0	11	Multifactor	Multifactor	NNP
12	24	cis-dominant	cis-dominant	JJ
25	33	negative	negative	JJ
34	44	regulation	regulation	NN
45	47	of	of	IN
48	52	IL-2	il-2	NN
53	57	gene	gene	NN
58	68	expression	expression	NN
69	71	in	in	IN
72	81	anergized	anergize	VBN
82	83	T	t	NN
84	89	cells	cell	NNS
89	90	.	.	.

92	95	The	the	DT
96	105	molecular	molecular	JJ
106	115	mechanism	mechanism	NN
116	126	underlying	underlie	VBG
127	131	IL-2	il-2	NN
132	147	transcriptional	transcriptional	JJ
148	156	blockade	blockade	NN
157	159	in	in	IN
160	167	anergic	anergic	JJ
168	169	T	t	NN
170	174	cell	cell	NN
175	181	clones	clone	NNS
182	184	is	be	VBZ
185	188	not	not	RB
189	194	fully	fully	RB
195	205	understood	understand	VBN
205	206	.	.	.

207	209	To	to	TO
210	217	examine	examine	VB
218	225	whether	whether	IN
226	228	an	an	DT
229	235	active	active	JJ
236	244	negative	negative	JJ
245	255	regulatory	regulatory	JJ
256	263	process	process	NN
264	270	occurs	occur	VBZ
270	271	,	,	,
272	274	we	we	PRP
275	282	created	create	VBD
283	284	a	a	DT
285	293	reporter	reporter	NN
294	303	construct	construct	NN
304	314	containing	contain	VBG
315	317	as	as	IN
318	320	an	an	DT
321	329	enhancer	enhancer	NN
330	334	four	four	CD
335	341	copies	copy	NNS
342	344	of	of	IN
345	348	the	the	DT
349	354	NF-AT	NF-AT	NNP
355	359	site	site	NN
360	363	and	and	CC
364	367	one	one	CD
368	372	copy	copy	NN
373	375	of	of	IN
376	379	the	the	DT
380	387	octamer	octamer	NN
388	392	site	site	NN
393	394	(	(	(
394	396	4X	4x	NN
397	406	NF-AT-Oct	NF-AT-Oct	NNP
406	407	)	)	)
407	408	.	.	.

409	413	This	this	DT
414	423	construct	construct	NN
424	427	was	be	VBD
428	432	only	only	RB
433	441	slightly	slightly	RB
442	449	reduced	reduce	VBN
450	451	(	(	(
451	459	1.3-fold	1.3-fold	RB
459	460	)	)	)
461	463	in	in	IN
464	467	its	its	PRP$
468	478	expression	expression	NN
479	483	when	when	WRB
484	494	stimulated	stimulate	VBN
495	500	under	under	IN
501	508	anergic	anergic	JJ
509	519	conditions	condition	NNS
519	520	,	,	,
521	526	while	while	IN
527	528	a	a	DT
529	534	whole	whole	JJ
535	540	mouse	mouse	NN
541	545	IL-2	il-2	NN
546	554	enhancer	enhancer	NN
555	564	construct	construct	NN
565	571	showed	show	VBD
572	573	a	a	DT
574	583	reduction	reduction	NN
584	586	of	of	IN
587	595	4.3-fold	4.3-fold	RB
595	596	.	.	.

597	605	Addition	addition	NN
606	608	of	of	IN
609	612	the	the	DT
613	617	-176	-176	CD
618	620	to	to	TO
621	624	-96	-96	CD
625	633	sequence	sequence	NN
634	636	to	to	TO
637	640	the	the	DT
641	643	4X	4x	NN
644	653	NF-AT-Oct	nf-at-oct	NN
654	663	construct	construct	NN
664	667	did	do	VBD
668	671	not	not	RB
672	678	impart	impart	VB
679	682	the	the	DT
683	690	ability	ability	NN
691	693	to	to	TO
694	696	be	be	VB
697	705	affected	affect	VBN
706	708	by	by	IN
709	715	anergy	anergy	NN
715	716	,	,	,
717	720	but	but	CC
721	729	addition	addition	NN
730	732	of	of	IN
733	736	the	the	DT
737	741	-236	-236	CD
742	744	to	to	TO
745	748	-96	-96	CD
749	757	sequence	sequence	NN
758	761	did	do	VBD
761	762	,	,	,
763	776	demonstrating	demonstrate	VBG
777	781	that	that	IN
782	788	anergy	anergy	NN
789	791	is	be	VBZ
792	794	an	an	DT
795	801	active	active	JJ
802	812	inhibitory	inhibitory	JJ
813	820	process	process	NN
821	824	and	and	CC
825	829	that	that	IN
830	834	more	more	JJR
835	839	than	than	IN
840	843	the	the	DT
844	852	presence	presence	NN
853	855	of	of	IN
856	859	the	the	DT
860	864	-150	-150	CD
865	869	AP-1	ap-1	NN
870	877	binding	binding	NN
878	882	site	site	NN
883	884	(	(	(
884	888	-152	-152	CD
889	891	to	to	TO
892	896	-147	-147	CD
896	897	)	)	)
898	900	is	be	VBZ
901	909	required	require	VBN
910	912	to	to	TO
913	920	mediate	mediate	VB
921	924	the	the	DT
925	931	effect	effect	NN
931	932	.	.	.

933	943	Mutational	mutational	JJ
944	951	studies	study	NNS
952	954	of	of	IN
955	958	the	the	DT
959	963	-236	-236	CD
964	966	to	to	TO
967	970	-96	-96	CD
971	979	sequence	sequence	NN
980	989	indicated	indicate	VBD
990	994	that	that	IN
995	998	the	the	DT
999	1007	presence	presence	NN
1008	1010	of	of	IN
1011	1015	both	both	CC
1016	1019	the	the	DT
1020	1024	-130	-130	CD
1025	1034	AP-1-like	ap-1-like	JJ
1035	1039	site	site	NN
1040	1041	(	(	(
1041	1045	-187	-187	CD
1046	1048	to	to	TO
1049	1053	-181	-181	CD
1053	1054	)	)	)
1055	1058	and	and	CC
1059	1062	the	the	DT
1063	1067	-150	-150	CD
1068	1076	proximal	proximal	JJ
1077	1081	AP-1	ap-1	NN
1082	1086	site	site	NN
1087	1091	were	be	VBD
1092	1101	necessary	necessary	JJ
1102	1104	to	to	TO
1105	1112	observe	observe	VB
1113	1119	anergy	anergy	NN
1119	1120	.	.	.

1121	1128	Because	because	IN
1129	1132	the	the	DT
1133	1137	-180	-180	CD
1138	1142	site	site	NN
1143	1145	is	be	VBZ
1146	1149	not	not	RB
1150	1158	required	require	VBN
1159	1162	for	for	IN
1163	1179	trans-activation	trans-activation	NN
1179	1180	,	,	,
1181	1183	it	it	PRP
1184	1187	was	be	VBD
1188	1196	possible	possible	JJ
1197	1199	to	to	TO
1200	1207	confirm	confirm	VB
1208	1210	by	by	IN
1211	1219	mutation	mutation	NN
1220	1222	in	in	IN
1223	1226	the	the	DT
1227	1233	normal	normal	JJ
1234	1239	mouse	mouse	NN
1240	1244	IL-2	il-2	NN
1245	1253	enhancer	enhancer	NN
1254	1258	that	that	IN
1259	1263	this	this	DT
1264	1268	site	site	NN
1269	1271	is	be	VBZ
1272	1282	absolutely	absolutely	RB
1283	1292	essential	essential	JJ
1293	1296	for	for	IN
1297	1303	anergy	anergy	NN
1304	1313	induction	induction	NN
1313	1314	.	.	.

1315	1318	The	the	DT
1319	1327	simplest	simple	JJS
1328	1333	model	model	NN
1334	1336	to	to	TO
1337	1344	explain	explain	VB
1345	1350	these	these	DT
1351	1358	results	result	NNS
1359	1361	is	be	VBZ
1362	1366	that	that	IN
1367	1373	anergy	anergy	NN
1374	1376	is	be	VBZ
1377	1385	mediated	mediate	VBN
1386	1388	by	by	IN
1389	1390	a	a	DT
1391	1398	complex	complex	NN
1399	1401	of	of	IN
1402	1410	multiple	multiple	JJ
1411	1424	transcription	transcription	NN
1425	1432	factors	factor	NNS
1433	1437	that	that	WDT
1438	1443	exert	exert	VBP
1444	1445	a	a	DT
1446	1456	cis-acting	cis-acting	JJ
1457	1465	dominant	dominant	JJ
1466	1474	negative	negative	JJ
1475	1485	regulatory	regulatory	JJ
1486	1492	effect	effect	NN
1493	1495	on	on	IN
1496	1499	the	the	DT
1500	1516	trans-activation	trans-activation	NN
1517	1519	of	of	IN
1520	1523	the	the	DT
1524	1528	IL-2	il-2	NN
1529	1533	gene	gene	NN
1533	1534	.	.	.